AXSMHealthcare · BiotechnologyThe 21 Wall Street analysts covering Axsome Therapeutics, Inc. hold a median 12-month price target of $280 — +31.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 15 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Axsome Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (93): The share price has been relatively steady.
Revisions (37): Analysts have, on balance, been cutting their forecasts.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AXSM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +31.0% from it.
Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | Mizuho | Maintains | Outperform | $306 → $316 |
| 11 Aug 2026 | Guggenheim | Maintains | Buy | $260 → $275 |
| 11 Aug 2026 | Morgan Stanley | Maintains | Equal-Weight | $242 → $251 |
| 11 Aug 2026 | Needham | Maintains | Buy | $267 → $268 |
| 11 Aug 2026 | RBC Capital | Maintains | Outperform | $304 → $297 |
| 11 Aug 2026 | Wells Fargo | Maintains | Overweight | $255 → $256 |
| 31 July 2026 | Mizuho | Maintains | Outperform | $310 → $306 |
| 31 July 2026 | Mizuho | Maintains | Outperform | — |
| 21 July 2026 | BMO Capital | Initiates | Outperform | $310 |
| 21 July 2026 | BMO Capital | Initiates | Outperform | — |
| 15 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $290 |
| 15 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $290 |
| 8 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 July 2026 | RBC Capital | Maintains | Outperform | — |
| 17 June 2026 | TD Cowen | Maintains | Buy | — |
| 5 May 2026 | Baird | Maintains | Outperform | — |
| 5 May 2026 | Guggenheim | Maintains | Buy | — |
| 5 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 May 2026 | Mizuho | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AXSM appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 12% of US stocks
Cheaper than 1% of US stocks
Cheaper than 95% of US stocks
Higher than 85% of US stocks
Higher than 77% of US stocks
Higher than 97% of US stocks
Higher than 21% of US stocks
Higher than 14% of US stocks
Higher than 6% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Axsome Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Axsome reported Q2 earnings that met estimates, although revenues missed forecasts. Sales of Auvelity and other products drove year-over-year revenue growth.
Why it matters — AXSM watchers would follow whether Auvelity and other product sales continue to support revenue growth against mixed quarterly results.
Axsome Therapeutics reported 46% year-on-year net product revenue growth in Q2 2026, led by Auvelity, but rising SG&A costs offset commercial gains and profitability remains out of reach.
Why it matters — A watcher would care because the company's path to profitability remains uncertain even as Auvelity's revenue grows, and management's ambitious peak sales target faces mounting skepticism.
Axsome Therapeutics posted downbeat results for the second quarter. Following these results, analysts increased their forecasts for the company.
Why it matters — AXSM watchers would care because analyst forecast increases after the earnings report signal revised expectations for the company's outlook.
Axsome Therapeutics held its Q2 2026 earnings call, and a transcript of the call was published by Seeking Alpha. The excerpt provides only the headline and source, with no financial details or commentary included.
Why it matters — A transcript of the Q2 2026 earnings call offers investors access to management's discussion of the company's recent performance and outlook.
Axsome Therapeutics reported its Q2 2026 financial results, with the article noting that key metrics can be compared to Wall Street estimates and year-ago figures.
Why it matters — The comparison of Axsome's key metrics to analyst estimates and prior-year figures provides investors with a framework for assessing the company's quarterly performance.
The 21 Wall Street analysts covering Axsome Therapeutics, Inc. have a median 12-month price target of $280, with estimates ranging from $246 to $380. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 21 analysts covering Axsome Therapeutics, Inc., 20 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Axsome Therapeutics, Inc. 73 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Axsome Therapeutics, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).
No one can know that. What the data says: the median 12-month target from 21 analysts implies +31.0% from the last close, and Ticker Nerd's factor model ranks Axsome Therapeutics, Inc. 73 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Axsome Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AXSM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $246 to $380 over the next 12 months.
Axsome Therapeutics, Inc. returned +96.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing therapies for central nervous system conditions with limited treatment options.
The most recent item we track (Zacks Investment Research, 11 Aug 2026): "Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues". Axsome reported Q2 earnings that met estimates, although revenues missed forecasts. Sales of Auvelity and other products drove year-over-year revenue growth.
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing therapies for central nervous system conditions with limited treatment options. Headquartered in New York City and founded in 2012, the company concentrates on neuropsychiatric and neurological disorders such as major depressive disorder, excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea, Alzheimer’s disease agitation, migraine, narcolepsy, and fibromyalgia. Axsome Therapeutics currently markets branded prescription CNS medicines, including Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness, distributed through pharmaceutical channels to adult patients under physician prescription. In parallel, it maintains a late-stage and clinical pipeline featuring differentiated small-molecule candidates like AXS-05, AXS-12, and AXS-14 targeting additional CNS indications. Operating as a single business segment, Axsome Therapeutics plays a specialized role in the healthcare market by addressing high unmet need in adult CNS disorders and supplying neurologists, psychiatrists, sleep specialists, and primary care physicians with novel therapeutic options.
CEO Dr. Herriot Tabuteau M.D. · 1,346 employees · United States · https://www.axsome.com